(Date:12/14/2009)... 14 Nektar Therapeutics (Nasdaq: NKTR ... appointed to serve on its board of directors. ... with over 35 years of experience in corporate ... to Nektar extensive industry perspective at an important ... Robin, President and CEO of Nektar and member ...
(Date:12/14/2009)... - Results From a Survey Conducted by UCB Assessing ... Countries , , - A third of ... impacts their enjoyment of the festive season, ... shopping for gifts, preparing holiday ... difficult to do, - Nearly ...
(Date:12/11/2009)... miRagen Therapeutics, Inc., a biopharmaceutical company focused ... therapeutics for cardiovascular and muscle disease, today announced ... plays a crucial role in the progression of ... and in neuromuscular synaptic regeneration in mice. ... of the journal Science , reveal miR-206 ...
(Date:12/11/2009)... Dec. 11 Ambit Biosciences Corporation announced today ... M. D. Anderson Cancer Center of the first patient ... E fficacy) Phase 2 pivotal trial ... (AML). AC220 is a novel, orally available, potent ... as a FMS-like tyrosine kinase-3 (FLT3) inhibitor. The ...
Breaking Biology Technology:Dennis Winger Joins Nektar Therapeutics' Board of Directors 2Dennis Winger Joins Nektar Therapeutics' Board of Directors 3Rheumatoid Arthritis Patients Want Pain-Free Days at Christmas 2Rheumatoid Arthritis Patients Want Pain-Free Days at Christmas 3Rheumatoid Arthritis Patients Want Pain-Free Days at Christmas 4miRagen announces discovery of key microRNA implicated in Lou Gehrig's disease 2Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 2Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 3Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 4Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 5... market is poised to exceed $539 million by 2012. Consumables, life ... areas that are expected to drive the industry,s growth in the ... ... 10, 2008 -- Economic trends, mergers & acquisitions in the industry, ...
... and LOS ANGELES, November 10 , - Current ... - Residual Risk Reduction Initiative (R3i) Calls for Action ... Standards,of Care in Millions of Patients With Heart Disease ... Europe, Asia,and Japan have come together today to launch ...
... and research group Plasma & Materials Processing (PMP) of ... awarded the Leverhulme Technology Transfer Award 2008. They receive ... for the research group) for their successful transfer of ... Hoex,s Ph.D. research was rewarded with the SolarWorld Junior ...
Other Biology Technology:Calorimeters and Thermal Analysis Equipment Market to Exceed $539 Million by 2012, According to New Report by Global Industry Analysts 2Calorimeters and Thermal Analysis Equipment Market to Exceed $539 Million by 2012, According to New Report by Global Industry Analysts 3Unique New Initiative by World-Recognized Specialists in Heart Disease and Diabetes to Reduce Residual Vascular Risk Launched Today 2Unique New Initiative by World-Recognized Specialists in Heart Disease and Diabetes to Reduce Residual Vascular Risk Launched Today 3TU/e awarded for knowledge transfer to solar energy industry 2Mouse monoclonal [002-49] to C1s ( Abpromise for all tested applications). entrezGeneID: 716 SwissProtID: P09871...
Rabbit polyclonal to Oct2, prediluted ( Abpromise for all tested applications). entrezGeneID: 5452 SwissProtID: P09086...
Selenoprotein P Purified Anti-Mouse clone 35, Isotype Mouse IgG 2b , 50 µg Consult technical datasheet for details....
Oct 2 Immunogen: Full length human protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products:Biology NavigationMedical Navigation